Daiichi Sankyo Co., Ltd. said it will delay publication of its annual earnings, a move that coincided with a sharp fall in its share price on Friday. The company rescheduled the earnings announcement from April 27 to May 11 as it conducts a review of its oncology portfolio and associated supply arrangements, and seeks additional time to determine the amount of loss provisions that may need to be recorded.
On the Tokyo exchange the stock fell nearly 10% to 2,505.5 yen, marking its lowest closing level since March 2022. The drop made the shares one of the weakest performers in the Nikkei 225 on the day, even as the broader index rose 0.3%.
In a press release, the company said it is reassessing supply plans for its oncology products and its development pipeline amid what it described as rapidly changing business conditions. That assessment, the statement said, has delayed the company’s ability to estimate the size of any loss provisions tied to contract manufacturers.
Daiichi Sankyo also pushed back the scheduled announcement of its five-year business plan, moving the disclosure forward to May 11 from an earlier date of May 19. The company framed the timing adjustments as necessary to ensure an accurate accounting of potential losses and to align strategy communications with the outcomes of its portfolio review.
The earnings delay occurs as the company continues a broader restructuring of its operations. Earlier in April, Daiichi Sankyo completed the sale of its over-the-counter unit, Daiichi Sankyo Healthcare, to Suntory Holdings; the sale was presented as part of an effort to concentrate on prescription medicines and its oncology pipeline.
Daiichi Sankyo has been directing resources toward oncology programs, highlighting assets such as Enhertu, a product it developed in collaboration with AstraZeneca. The company’s statement emphasized that the evolving commercial and manufacturing circumstances for its oncology portfolio require additional analysis before it can finalize financial provisions and related disclosures.
Investors will now await the consolidated results and the updated five-year plan when both are released on May 11, which should provide more detail on the company’s assessment of supply risks, any loss provisions related to contract manufacturing, and the strategic direction for its prescription and oncology focus.